[go: up one dir, main page]

KR910700352A - Expression of Plasmodium Circus Sporozoite Protein in Insect Cells - Google Patents

Expression of Plasmodium Circus Sporozoite Protein in Insect Cells Download PDF

Info

Publication number
KR910700352A
KR910700352A KR1019900701860A KR900701860A KR910700352A KR 910700352 A KR910700352 A KR 910700352A KR 1019900701860 A KR1019900701860 A KR 1019900701860A KR 900701860 A KR900701860 A KR 900701860A KR 910700352 A KR910700352 A KR 910700352A
Authority
KR
South Korea
Prior art keywords
protein
gene expression
expression unit
cell
cells
Prior art date
Application number
KR1019900701860A
Other languages
Korean (ko)
Inventor
볼렌 알렉스
길레스 파스칼
하인데릭크스 미쉘
야콥스 폴
랑크 요한센 한네
맛사에르 마르크
로젠버어그 마틴
Original Assignee
스미스클라인 바이올로지칼즈(s.a.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스미스클라인 바이올로지칼즈(s.a.) filed Critical 스미스클라인 바이올로지칼즈(s.a.)
Publication of KR910700352A publication Critical patent/KR910700352A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/866—Baculoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음.No content.

Description

곤충 세포내에서 플라스모듐 서컴스포로 조이트 단백질의 발현Expression of Plasmodium Circus Sporozoite Protein in Insect Cells

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (35)

플라스모듐 CS 단백질에 대한 DNA 암호화 서열 및 암호화 서열의 전사 및 곤충세포내에서의 해독에 필요한 조절 요소로 구성되는 플라스모듐 CS 단백질 유전자 발현 단위.A Plasmodium CS protein gene expression unit consisting of DNA coding sequence for Plasmodium CS protein and regulatory elements necessary for transcription of the coding sequence and translation in insect cells. 제1항에 있어서, P.팔시패럼 CS 단백질을 암호화하는 유전자 발현 단위.The gene expression unit of claim 1, which encodes a P. falcirum CS protein. 제2항에 있어서, 카르복시 말단 앵커 서열이 결여되거나 또는 시그널 서열이 결여되거나 또는 시그널 및 앵커 서열 모두가 결여된 단백질 암호화하는 유전자 발현 단위.The gene expression unit of claim 2, which encodes a protein lacking a carboxy terminal anchor sequence or lacking a signal sequence or lacking both a signal and an anchor sequence. 제3항에 있어서, 조절 요소가 드로조필라 세포내에서 기능하는 유전자 발현 단위.4. The gene expression unit of claim 3, wherein the regulatory element functions in the drozophila cell. 제3항에 있어서, 조절 요소가 레피도프테라 세포내에서 기능하는 유전자 발현 단위.4. The gene expression unit of claim 3, wherein the regulatory element functions in Repidoptera cells. 제4항에 있어서, 상기 조절 요소가 액틴 5c 프로모터 또는 드로조필라 메탈로티오네인 프로모터로 구성되는 유전자 발현 단위.5. The gene expression unit of claim 4, wherein said regulatory element is comprised of an actin 5c promoter or a drozophyla metallothionein promoter. 제6항에 있어서, pMTcsp 391, pMTcsp 398, 또는 pMTcsp 412 내에 존재하는 유전자 발현 단위.The gene expression unit of claim 6 which is present in pMTcsp 391, pMTcsp 398, or pMTcsp 412. 제5항에 있어서, 조절 요소가 스포도프테라프루기페르다 세포내에서 기능하는 유전자 발현 단위.6. The gene expression unit of claim 5, wherein the regulatory element functions in Spodovterapuriferda cells. 제8항에 있어서, 상기 조절 요소가 AcMNPV 폴리헤드린 유전자 프로모터로 구성되는 유전자 발현 단위.The gene expression unit of claim 8, wherein said regulatory element consists of an AcMNPV polyhedrin gene promoter. 제1항의 유전자 발현 단위를 포함하는 DNA 벡터.A DNA vector comprising the gene expression unit of claim 1. 제1항의 유전자 발현 단위를 포함하는 재조합 바큘로비루스.A recombinant baculovirus comprising the gene expression unit of claim 1. 제10항에 벡터로 트랜스팩트된 곤충세포.An insect cell transfected with the vector of claim 10. 제12항에 있어서, 드로조필라 세포인 곤충세포.13. The insect cell of claim 12 which is a drozophila cell. 제11항의 재조합 바큘로비루스로 트랜스팩트된 곤충세포.An insect cell transfected with the recombinant baculovirus of claim 11. 제14항에 있어서, 레피도프테라 세포인 곤충세포.The insect cell according to claim 14, which is a Redodoterra cell. 제15항에 있어서, 곤충세포가 S.프로기페르다인 곤충세포.16. The insect cell of claim 15, wherein the insect cell is S. progiferda. 곤충세포내에서 생산된 P.팔시패럼 CS 단백질.P. falciparum CS protein produced in insect cells. 제17항에 있어서, 완전한 길이의 CS 단백질인 단백질.The protein of claim 17, which is a CS protein of full length. 제17항에 있어서, 카르복시 말단 앵커 영역이 결여되거나 또는 시그널 펩티드가 결여되거나 또는 시그널 펩티드 및 카르복시 말단 앵커 영역이 모두 결여된 단백질인 단백질.The protein of claim 17, which is a protein lacking a carboxy terminal anchor region or lacking a signal peptide or lacking both a signal peptide and a carboxy terminal anchor region. 제1항의 유전자 발현 단위에 의해 암호화된, 곤충세포내에서 생산된 단백질.A protein produced in an insect cell encoded by the gene expression unit of claim 1. 제3항의 유전자 발현 단위에 의해 암호화된, 곤충세포내에서 생산된 단백질.A protein produced in an insect cell encoded by the gene expression unit of claim 3. 제1항의 CS 유전자 발현 단위에 의해 암호화된 단백질을 면역보호성 및 무=독성 양만큼 포함하는, 말라리아성 감염에 대한 보호를 자극하는 백신.A vaccine that stimulates protection against malaria infection, comprising a protein encoded by the CS gene expression unit of claim 1 in an immunoprotective and non-toxic amount. 안전하고 효과적인 양의 제22항의 백신을 인간에게 투여하는 것으로 구성되는, 말라리아성 감염과 관련된 병 증상에 대해서 인간을 보호하는 방법.A method of protecting a human against disease symptoms associated with malaria infection, comprising administering to the human a safe and effective amount of the vaccine of claim 22. 플라소모듐 CS 단백질 유전자 발현 단위로 트랜스팩트된, 상기 단백질을 발현시킬 수 있는 곤충세포를 적절한 배지내에서 배양하는 것으로 구성되는, 곤충세포내에서 플라스모듐 CS 단백질의 생산방법.A method of producing plasmodium CS protein in insect cells, comprising culturing insect cells capable of expressing the protein, transfected with a plasmodium CS protein gene expression unit, in an appropriate medium. 제24항에 있어서, 상기 곤충세포가 드로조필라 세포인 방법.The method of claim 24, wherein said insect cell is a drozophila cell. 제25항에 있어서, 상기 세포가, 하이그로마이신 B 포스포트랜스퍼라제에 대한 암호화 서열을 포함하는 제1벡터 및 플라스모듐 CS 단백질 유전자 발현 단위에 대한 암호화 서열을 포함하는 제2벡터로 트랜스팩트되는 방법.The cell of claim 25, wherein the cell is transfected with a first vector comprising the coding sequence for hygromycin B phosphotransferase and a second vector comprising the coding sequence for the Plasmodium CS protein gene expression unit How to be. 제26항에 있어서, 상기 제1벡터가 pCOHYGRO인 방법.The method of claim 26, wherein the first vector is pCOHYGRO. 제26항에 있어서, 상기 제2벡터가 pMTcsp 391, pMTcsp 398, 또는 pMTcsp 412의 CS DNA 암호화 서열로 구성되는 방법.The method of claim 26, wherein the second vector consists of a CS DNA coding sequence of pMTcsp 391, pMTcsp 398, or pMTcsp 412. 제25항에 있어서, 상기 드로조필라 세포가 D.멜라노가스터 S2세포인 방법.27. The method of claim 25, wherein said drozofila cells are D. melanogasster S 2 cells. 제29항에 있어서, 상기 S2세포가, 벡터 pCOHYGRO 및 pMTcsp 391, pMTcsp 398, 또는 pMTcsp 412 내에 존재하는 것과 같은 CS 유전자 발현 단위를 포함하는 벡터로 동시-트랜스팩트되는 방법.The method of claim 29, wherein said S 2 cells are co-transfected with a vector comprising a CS gene expression unit, such as present in vectors pCOHYGRO and pMTcsp 391, pMTcsp 398, or pMTcsp 412. 제24항에 있어서, 상기 곤충세포가 레피도프테라 세포인 방법.25. The method of claim 24, wherein said insect cell is a Redodorfter cell. 제31항에 있어서, 상기 세포가 바큘로비루스 DNA로 구성되는 제1벡터 및 플라스모듐 CS 유전자 발현 단위에 대한 암호화 서열을 포함하는 플라스미드 DNA로 구성되는 제2벡터로 동시-트랜스팩트되는 방법.32. The method of claim 31, wherein said cells are co-transfected with a first vector consisting of baculovirus DNA and a second vector consisting of plasmid DNA comprising the coding sequence for the Plasmodium CS gene expression unit. 제31항에 있어서, 상기 레피오프테라 세포가 S.프루기페르다인 방법.32. The method of claim 31, wherein said lepioptera cells are S. pruiferferda. 제24항의 방법에 의해 생산된 CS 단백질을 면역보호성 및 무독성 양만큼 포함하는, 말라리아성 감염에 대한 보호를 자극하는 백신.A vaccine that stimulates protection against malaria infection, comprising the CS protein produced by the method of claim 24 in an immunoprotective and non-toxic amount. 상기 단백질이 말라리아성 감염에 대한 보호를 자극하는 백신의 제조에 사용되는 제20항의 단백질.The protein of claim 20, wherein the protein is used to prepare a vaccine that stimulates protection against malaria infection. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019900701860A 1988-12-21 1989-12-13 Expression of Plasmodium Circus Sporozoite Protein in Insect Cells KR910700352A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28793488A 1988-12-21 1988-12-21
US287.934 1988-12-21
PCT/US1989/005550 WO1990007006A1 (en) 1988-12-21 1989-12-13 Expression of the plasmodium circumsporozoite protein in insect cells

Publications (1)

Publication Number Publication Date
KR910700352A true KR910700352A (en) 1991-03-14

Family

ID=23105005

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900701860A KR910700352A (en) 1988-12-21 1989-12-13 Expression of Plasmodium Circus Sporozoite Protein in Insect Cells

Country Status (11)

Country Link
EP (1) EP0409923A4 (en)
JP (1) JPH03504082A (en)
KR (1) KR910700352A (en)
AU (1) AU634512B2 (en)
CA (1) CA2005512A1 (en)
DK (1) DK187790A (en)
IL (1) IL92782A0 (en)
NZ (1) NZ231795A (en)
PT (1) PT92677A (en)
WO (1) WO1990007006A1 (en)
ZA (1) ZA899610B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003794C (en) * 1988-12-01 2000-02-08 Hanne R. Johansen Expression of hiv proteins in drosophila cells
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) * 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4707357A (en) * 1984-06-26 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Immunologically active peptides capable of inducing immunization against malaria and genes encoding therefor
WO1988005817A1 (en) * 1987-01-30 1988-08-11 Smith Kline - Rit S.A. Expression of the p. falciparum circumsporozoite protein by yeast
CA1341345C (en) * 1987-05-08 2002-03-05 Hanne Ranch Johansen Expression of foreign genes in drosophila cells

Also Published As

Publication number Publication date
JPH03504082A (en) 1991-09-12
WO1990007006A1 (en) 1990-06-28
DK187790D0 (en) 1990-08-06
EP0409923A1 (en) 1991-01-30
AU4803790A (en) 1990-07-10
AU634512B2 (en) 1993-02-25
NZ231795A (en) 1992-04-28
EP0409923A4 (en) 1993-01-20
IL92782A0 (en) 1990-09-17
PT92677A (en) 1990-06-29
DK187790A (en) 1990-08-06
ZA899610B (en) 1990-11-28
CA2005512A1 (en) 1990-06-21

Similar Documents

Publication Publication Date Title
KR850004273A (en) Recombinant gamma interferon with increased stability and preparation method thereof
DE69829668D1 (en) PREPARATION AND USE OF RECOMBINANT INFLUENZA A VIRUS M2 CONSTRUCTIONS AND IMPORTS
KR880700858A (en) Growth Factors of Recombinant Human Endothelial Cells
DK2107109T3 (en) Recombinant vascular endothelial cell growth factor D (VEGF-D)
KR910001060A (en) New compounds
ATE227584T1 (en) SUBUNITY VACCINE AGAINST FLAVIVIRUS INFECTION
ATE146219T1 (en) POLYPEPTIDE
KR900018373A (en) Recombinant baculovirus, an envelope protein of Japanese encephalitis virus using the virus, and a method for producing the protein.
KR890005269A (en) Recombinant Apoxvirus
IL70776A (en) Recombinant dna molecule encoding at least one polypeptide displaying the immunogenicity of at least one merozoite antigen or asexual blood stage antigen of p.falciparum,vectors comprising the dna molecule,host cells transformed thereby,immunogenic polypeptides produced by host cells and compositions containing the polypeptides
RU2000107129A (en) CHEMISTRY VACCINE AGAINST Tick-borne encephalitis virus
BR9712556A (en) Plasmid, pharmaceutical composition, and, process of immunizing an individual against an antigen
ES2174530T3 (en) IFNAR / IFN COMPLEX.
KR910700352A (en) Expression of Plasmodium Circus Sporozoite Protein in Insect Cells
ATE104349T1 (en) VACCINE AGAINST COCCIDIOSIS.
KR880009991A (en) Polypeptide with Anticoagulant Action
ATE232903T1 (en) VACCINE AGAINST POULTRY COCCIDOSE
AU625713B2 (en) Method for producing recombinant protein derived from the circumsporozoite gene of plasmodium falciparum
CA2158024A1 (en) A mycoplasma gallisepticum antigen, dna encoding the antigen, recombinant vector bearing the dna and recombinant virus utilizing the recombinant vector as well as use thereof
DK0871738T3 (en) Recombinant viral pseudoparticles and their use as vaccines or antitumor drugs
KR950700415A (en) Malaria vaccine (IMPROVEMENTS IN OR RELATING TO MALARIA VACCINE)
NZ507983A (en) A polypeptide comprising the amino acid of an n- terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
ES8605296A1 (en) Recominant factor VIII-R.
KR920012116A (en) Protective Plasmodium Fassiparum Hybrid Proteins Containing Sub-Sequences of Malaria Antigens HRPII and SERP, Methods for Making and Uses thereof
FR2676068B1 (en) IMMUNOGENIC RECOMBINANT STRAINS OF B. ANTHRACIS - IMMUNOGENIC COMPOSITIONS CONTAINING THEM.

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19900822

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid